Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5361048 | 0.83 | ACHE (0.54) | ACHE | |
| SCHEMBL5350686 | 0.82 | ACHE (0.52) | ACHE | |
| SCHEMBL12719136 | 0.81 | ACHE (0.55) | ACHE | |
| SCHEMBL4858398 | 0.81 | ACHE (0.56) | ACHE | |
| SCHEMBL4853298 | 0.80 | ACHE (0.55) | ACHE | |
| SCHEMBL10696327 | 0.79 | ACHE (0.59) | ACHE | |
| SCHEMBL10426976 | 0.75 | ACHE (0.54) | ACHE | |
| SCHEMBL10427190 | 0.74 | ACHE (0.52) | ACHE | |
| SCHEMBL2414659 | 0.73 | ACHE (0.46) | ACHE | |
| SCHEMBL8599920 | 0.72 | ACHE (0.58) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070027138-A1 | Derivatives and analogs of galanthamine | SANOCHEMIA PHARMAZEUTIKA AKTIENGESELLSCHAFT | 2007-02-01 | — | — | US | disclosed |
| US-7166588-B2 | Derivatives and analogs of galanthamine | SANOCHEMIA PHARMAZEUTIKA AKTIENGESELLSCHAFT (AT) | 2007-01-23 | — | — | US | disclosed |
| EP-1181294-B1 | NOVEL DERIVATIVES AND ANALOGUES OF GALANTHAMIN | SANOCHEMIA PHARMAZEUTIKA AG (AT) | 2004-03-31 | — | — | EP | disclosed |
| US-20030199493-A1 | Novel derivatives and analogues of galanthamin | SANOCHEMIA PHARMAZEUTIKA AKTIENGESELLSCHAFT (AT) | 2003-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027138-A1 | Derivatives and analogs of galanthamine | GALR2, GALR1, GALR3 | ACHE 183/4885PDE4D 1564/4885 |
| US-20030199493-A1 | Novel derivatives and analogues of galanthamin | GALR1, GALNT1, GALK1 | ACHE 720/4885PDE4D 3811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.